SPRB Jun 2024 0.500 call
| Previous close | 0.3500 |
| Open | 0.3500 |
| Bid | 0.0000 |
| Ask | 0.4000 |
| Strike | 0.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.3500 - 0.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 23 |
Business WireSpruce Biosciences Recognized as a Bay Area Best Place to Work
SOUTH SAN FRANCISCO, Calif., June 06, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Business Journal have recognized the company as a Best Place to Work in 2024.
Business WireSpruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
SOUTH SAN FRANCISCO, Calif. & MUNICH, June 04, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, and HMNC Brain Health GmbH ("HMNC"), a global precision psychiatry biopharma company, announced today a strategic collaboration to develop Spruce’s investigational product candidate, tildacerfont, a second-generation CRF
Business WireSpruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
SOUTH SAN FRANCISCO, Calif., June 03, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine disorders with significant unmet medical need, presented results from its Phase 2 POWER study of tildacerfont, a second-generation CRF1 receptor antagonist, for the treatment of polycystic ovary syndrome (PCOS) at the 2024 Annual Meeting of the Endocrine Society (ENDO 2024).
